Abstract PO046: Interaction between Desmoglein2 and hypoxia controls breast cancer metastasis

Abstract

Abstract Breast cancer is the most common cancer of women worldwide. Although the 5-year survival rate has greatly improved due to early detection and advance in therapeutic strategies, metastasis remains the major cause of breast cancer death. Metastatic cancer cells which formed clusters of circulating tumor cells (CTCs) are particularly associated with colonization of distant organs and poor prognosis. However, the key factors required for tumor cell dissemination and CTC clustering remain elusive. We found that Desmoglein2 (DSG2), a cell adhesion molecule involved in desmosome mediated intercellular adhesion, promoted tumor growth, increased the prevalence of CTC clusters and facilitated distant organ colonization. Importantly, regulation of DSG2 by hypoxia was a key to this process. Hypoxia-induced DSG2 downregulation led to elevated epithelial-mesenchymal transition (EMT) gene expression allowing cells to detach from the primary tumor and undergo intravasation. Subsequent reactivation of DSG2 expression after release of hypoxic stress in the circulation allowed CTCs to colonize distant organs. This dynamic regulation of DSG2 was mediated by Hypoxia-Induced Factor1α (HIF1α). In contrast to its more widely observed function to activate expression of hypoxia-inducible genes, HIF1α repressed DSG2 by recruitment of the Polycomb Repressive Complex 2 components, EZH2 and SUZ12, to the DSG2 promoter. Consistent with our experimental data, DSG2 expression level correlated with poor prognosis and recurrence risk in breast cancer patients. Together, these results demonstrated the importance of DSG2 expression in metastasis and revealed a new mechanism by which hypoxia drives metastasis. Citation Format: Wendy W. Hwang-Verslues, Po-Hao Chang. Interaction between Desmoglein2 and hypoxia controls breast cancer metastasis [abstract]. In: Proceedings of the AACR Virtual Special Conference on the Evolving Tumor Microenvironment in Cancer Progression: Mechanisms and Emerging Therapeutic Opportunities; in association with the Tumor Microenvironment (TME) Working Group; 2021 Jan 11-12. Philadelphia (PA): AACR; Cancer Res 2021;81(5 Suppl):Abstract nr PO046.